Tisotumab vedotin

Indicaton

Tisotumab vedotin (TV) is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen and is being developed in cervical cancer as well as other solid tumors.

Therapeutic indications

Oncology

Type of product

Antibody

Table

Phase

Phase II started
Partnering status

Partnered
Partner

Genmab A/S

You may also be interested in

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

Marketed

MV-004

MV-004 is an orally available recombinant bacterial enzyme acting in the small intesine to adaptively modulate microbiota function during cancer immunotherapy. MV004 has been conceived to convert the majority of patients with solid tumors non-responding to immune checkpoint blockade (ICB) to responders.

Discovery

4D Lifetest Lung Dx, 4D Lifetest Breast Dx, 4D Lifetest Colon Dx, 4D Lifetest Prostate Dx

4D Lifetest™ is our flagship product and the first non-invasive CE IVD certified blood liquid biopsy assay to assess cancer formation due to its unique transformational biomarker at its earliest stage. This diagnostic information enables eraly invention and is a breakthrough progress to reduce mortality rates of cancer patients and protect benign patients from the invasive stress of frequently repeated surveillance diagnostics.The assay is CE IVD certified for the early detection of lung, breast, prostate and colon cancer and comercially available via our commercialization partner Medicover.

Marketed